Peptidyl prolyl isomerase, Pin1 is a potential target for enhancing the therapeutic efficacy of etoposide

Current Cancer Drug Targets

Volumn 11, Issue 3, 2011, Pages 380-392

  Mathur, R ^a,b   Chandna, S ^a   Kapoor, P N ^c   Dwarakanath, B S ^a  

^a INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

^b UNIVERSITY OF DELHI   (India)

^c UNIVERSITY OF DELHI   (India)

Author keywords

Apoptosis; Cell proliferation; Cell survival; Etoposide; Juglone; Micronuclei; Pin1; Therapeutic efficacy; Topoisomerase II

Indexed keywords

DNA; ETOPOSIDE; JUGLONE; PEPTIDYLPROLYL ISOMERASE PIN1;

APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; CYTOGENETICS; DNA DAMAGE; DNA DEGRADATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NICK END LABELING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; DNA DAMAGE; DRUG SYNERGISM; ENZYME INHIBITORS; ETOPOSIDE; FLOW CYTOMETRY; HUMANS; LUNG NEOPLASMS; MICRONUCLEUS TESTS; NAPHTHOQUINONES; PEPTIDYLPROLYL ISOMERASE; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 79951708802     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800911794519761     Document Type: Article

References (60)

1. Champoux, J. J. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 2001, 70, 369-413.
2. Chen, A. Y.; Liu, L. F. Design of topoisomerase inhibitors to overcome MDR1-mediated drug resistance. Adv. Pharmacol. 1994, 29B, 245-256.
3. Varga-Weisz, P. D.; Wilm, M.; Bonte, E.; Dumas, K.; Mann, M.; Becker, P. B. Chromatin-remodelling factor CHRAC contains the ATPases ISWI and topoisomerase II. Nature 1997, 388, 598-602.
4. Fry, A. M.; Chresta, C. M.; Davies, S. M.; Walker, M. C.; Harris, A. L.; Hartley, J. A.; Masters, J. R.; Hickson, I. D. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res. 1991, 51, 6592-6595.
5. Davis, P. L.; Shaiu, W. L.; Scott, G. L.; Iglehart, J. D.; Hsieh, T. S.; Marks, J. R. Complex response of breast epithelial cell lines to topoisomerase inhibitors. Anticancer Res. 1998, 18, 2919-2932.
6. Smit, E. F.; Carney, D. N.; Harford, P.; Sleijfer, D. T.; Postmus, P.E. A phase II study of oral etoposide in elderly patients with small cell lung cancer. Thorax 1989, 44, 631-633.
7. Kubota, Y.; Toyoda, Y.; Kubota, H.; Asada, A.; Sugiyama, K. Treatment of atelectasis with selective bronchial suctioning. Use of a curved-tipped catheter with a guide mark. Chest 1991, 99, 510-512.
8. McLeod, H. L.; Douglas, F.; Oates, M.; Symonds, R. P.; Prakash, D.; van der Zee, A. G.; Kaye, S. B.; Brown, R.; Keith, W. N. Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int. J. Cancer 1994, 59, 607-611.
9. Klein, C. E.; Tangen, C. M.; Braun, T. J.; Hussain, M. H.; Peereboom, D. M.; Nichols, C. R.; Rivkin, S. E.; Dakhil, S. R.; Crawford, E. D. SWOG-9510: evaluation of topotecan in hormone refractory prostate cancer: a Southwest Oncology Group study. Prostate 2002, 52, 264-268.
10. Hande, K. R. Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim. Biophys. Acta 1998, 1400, 173-184.
11. Dwarakanath, B. S.; Khaitan, D.; Mathur, R. Inhibitors of topoisomerases as anticancer drugs: problems and prospects. Indian J. Exp. Biol. 2004, 42, 649-659.
12. Megonigal, M. D.; Fertala, J.; Bjornsti, M. A. Alterations in the catalytic activity of yeast DNA topoisomerase I result in cell cycle arrest and cell death. J. Biol. Chem. 1997, 272, 12801-12808.
13. Fernandes, D. J.; Danks, M. K.; Beck, W. T. Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA. Biochemistry (Mosc.) 1990, 29, 4235-4241.
14. Dwarakanath, B. S.; Wallen, C. A.; St Clair, D. K.; Wheeler, K. T. Characterization of nuclear matrices prepared without salt extraction. Anal. Biochem. 1991, 198, 68-74.
15. Turley, H.; Comley, M.; Houlbrook, S.; Nozaki, N.; Kikuchi, A.; Hickson, I. D.; Gatter, K.; Harris, A. L. The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Br. J. Cancer 1997, 75, 1340-1346.
16. Valkov, N. I.; Gump, J. L.; Sullivan, D. M. Quantitative immunofluorescence and immunoelectron microscopy of the topoisomerase II alpha associated with nuclear matrices from wildtype and drug-resistant chinese hamster ovary cell lines. J. Cell. Biochem. 1997, 67, 112-130.
17. Valkov, N. I.; Sullivan, D. M. Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma. Semin. Hematol. 1997, 34, 48-62.
18. Dingemans, A. M.; Pinedo, H. M.; Giaccone, G. Clinical resistance to topoisomerase-targeted drugs. Biochim. Biophys. Acta 1998, 1400, 275-288.
19. Tolner, B.; Hartley, J. A.; Hochhauser, D. Transcriptional regulation of topoisomerase II alpha at confluence and pharmacological modulation of expression by bis-benzimidazole drugs. Mol. Pharmacol. 2001, 59, 699-706.
20. Adhikari, J. S.; Dwarakanath, B. S.; Mathur, R.; Ravindranath, T. Alterations in radiation induced cell cycle perturbations by 2 deoxy-D-glucose in human tumor cell lines. Indian J. Exp. Biol. 2003, 41, 1392-1399.
21. Dwarakanath, B. S.; Khaitan, D.; Ravindranath, T. 2-deoxy-D-glucose enhances the cytotoxicity of topoisomerase inhibitors in human tumor cell lines. Cancer Biol. Ther. 2004, 3, 864-870.
22. Gupta, S.; Mathur, R.; Dwarakanath, B. S. The glycolytic inhibitor 2-deoxy-D-glucose enhances the efficacy of etoposide in ehrlich ascites tumor-bearing mice. Cancer Biol. Ther. 2005, 4, 87-94.
23. Kurtoglu, M.; Gao, N.; Shang, J.; Maher, J. C.; Lehrman, M. A.; Wangpaichitr, M.; Savaraj, N.; Lane, A. N.; Lampidis, T. J. Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol. Cancer Ther. 2007, 6, 3049-3058.
24. Wells, N. J.; Fry, A. M.; Guano, F.; Norbury, C.; Hickson, I. D. Cell cycle phase-specific phosphorylation of human topoisomerase II alpha. Evidence of a role for protein kinase C. J. Biol. Chem. 1995, 270, 28357-28363.
25. Ishida, R.; Iwai, M.; Marsh, K. L.; Austin, C. A.; Yano, T.; Shibata, M.; Nozaki, N.; Hara, A. Threonine 1342 in human topoisomerase IIalpha is phosphorylated throughout the cell cycle. J. Biol. Chem. 1996, 271, 30077-30082.
26. Crenshaw, D. G.; Yang, J.; Means, A. R.; Kornbluth, S. The mitotic peptidyl-prolyl isomerase, Pin1, interacts with Cdc25 and Plx1. EMBO J. 1998, 17, 1315-1327.
27. Lu, P. J.; Zhou, X. Z.; Shen, M.; Lu, K. P. Function of WW domains as phosphoserine or phosphothreonine-binding modules. Science 1999, 283, 1325-1328.
28. Ryo, A.; Nakamura, M.; Wulf, G.; Liou, Y. C.; Lu, K. P. Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat. Cell Biol. 2001, 3, 793-801.
29. Wulf, G. M.; Ryo, A.; Wulf, G. G.; Lee, S. W.; Niu, T.; Petkova, V.; Lu, K. P. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J. 2001, 20, 3459-3472.
30. Ayala, G.; Wang, D.; Wulf, G.; Frolov, A.; Li, R.; Sowadski, J.; Wheeler, T. M.; Lu, K. P.; Bao, L. The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res. 2003, 63, 6244-6251.
31. Bao, L.; Kimzey, A.; Sauter, G.; Sowadski, J. M.; Lu, K. P.; Wang, D. G. Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am. J. Pathol. 2004, 164, 1727-1737.
32. Lill, C.; Schneider, S.; Pammer, J.; Loewe, R.; Gedlicka, W.; Houben, R.; Heiduschka, G.; Brunner, M.; Thurnher, D. Significant correlation of peptidyl-prolyl isomerase overexpression in merkel cell carcinoma with overall survival of patients. Head Neck 2010.
33. Khanal, P.; Namgoong, G. M.; Kang, B. S.; Woo, E. R.; Choi, H. S. The prolyl isomerase Pin1 enhances HER-2 expression and cellular transformation via its interaction with mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1. Mol. Cancer Ther. 2010, 9, 606-616.
34. Liou, Y. C.; Ryo, A.; Huang, H. K.; Lu, P. J.; Bronson, R.; Fujimori, F.; Uchida, T.; Hunter, T.; Lu, K. P. Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes. Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 1335-1340.
35. Ryo, A.; Liou, Y. C.; Wulf, G.; Nakamura, M.; Lee, S. W.; Lu, K. P. PIN1 is an E2F target gene essential for Neu/Ras-induced transformation of mammary epithelial cells. Mol. Cell. Biol. 2002, 22, 5281-5295.
36. Ryo, A.; Liou, Y. C.; Lu, K. P.; Wulf, G. Prolyl isomerase Pin1: a catalyst for oncogenesis and a potential therapeutic target in cancer. J. Cell Sci. 2003, 116, 773-783.
37. Messenger, M. M.; Saulnier, R. B.; Gilchrist, A. D.; Diamond, P.; Gorbsky, G. J.; Litchfield, D. W. Interactions between protein kinase CK2 and Pin1. Evidence for phosphorylation-dependent interactions. J. Biol. Chem. 2002, 277, 23054-23064.
38. Albert, A. L.; Lavoie, S. B.; Vincent, M. Multisite phosphorylation of Pin1-associated mitotic phosphoproteins revealed by monoclonal antibodies MPM-2 and CC-3. BMC Cell Biol. 2004, 5, 22.
39. Xu, Y. X.; Manley, J. L. The prolyl isomerase Pin1 functions in mitotic chromosome condensation. Mol. Cell 2007, 26, 287-300.
40. Mathur, R. Experimental studies on the modification of cellular responses to topoisomerase inhibitors in normal and transformed cell lines. Ph. D. Thesis, University of Delhi 2008.
41. Mathur, R.; Suman, S.; Beaume, N.; Ali, M.; Bhatt, A. N.; Chopra, M.; Saluja, D.; Mishra, A. K.; Chandna, S.; Kapoor, P. N.; Dwarakanath, B. S. Interaction and structural modification of topoisomerase IIalpha by peptidyl prolyl isomerase, pin1: an in silico study. Protein Pept. Lett. 2010, 17, 151-163.
42. Dwarkanath, B. S.; Jain, V. K. Energy linked modifications of the radiation response in a human cerebral glioma cell line. Int. J. Radiat. Oncol. Biol. Phys. 1989, 17, 1033-1040.
43. Dwarakanath, B. S.; Jain, V. K. Enhancement of radiation damage by 2-deoxy-D-glucose in organ cultures of brain tumours. Indian J. Med. Res. 1985, 82, 266-268.
44. Countryman, P. I.; Heddle, J. A. The production of micronuclei from chromosome aberrations in irradiated cultures of human lymphocytes. Mutat. Res. 1976, 41, 321-332.
45. Ostling, O.; Johanson, K. J. Microelectrophoretic study of radiation-induced DNA damages in individual mammalian cells. Biochem. Biophys. Res. Commun. 1984, 123, 291-298.
46. Chandna, S. Single-cell gel electrophoresis assay monitors precise kinetics of DNA fragmentation induced during programmed cell death. Cytometry A 2004, 61, 127-133.
47. Willmore, E.; Frank, A. J.; Padget, K.; Tilby, M. J.; Austin, C. A. Etoposide targets topoisomerase IIalpha and IIbeta in leukemic cells: isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique. Mol. Pharmacol. 1998, 54, 78-85.
48. Lin, C. W.; Darzynkiewicz, Z.; Li, X.; Traganos, F.; Bedner, E.; Tse-Dinh, Y. C. Differential expression of human topoisomerase IIIalpha during the cell cycle progression in HL-60 leukemia cells and human peripheral blood lymphocytes. Exp. Cell Res. 2000, 256, 225-236.
49. Singh, S.; Dwarakanath, B. S.; Lazar Mathew, T. Role of topoisomerases in cytotoxicity induced by DNA ligand Hoechst 33342 and UV-C in a glioma cell line. Indian J. Exp. Biol. 2005, 43, 313-323.
50. Clifford, B.; Beljin, M.; Stark, G. R.; Taylor, W. R. G2 arrest in response to topoisomerase II inhibitors: the role of p53. Cancer Res. 2003, 63, 4074-4081.
51. Kaufmann, S. H. Cell death induced by topoisomerase-targeted drugs: more questions than answers. Biochim. Biophys. Acta 1998, 1400, 195-211.
52. Brock, W. A.; Williams, M. Kinetics of micronucleus expression in synchronized irradiated Chinese hamster ovary cells. Cell Tissue Kinet. 1985, 18, 247-254.
53. Burden, D. A.; Osheroff, N. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim. Biophys. Acta 1998, 1400, 139-154.
54. Cuvier, O.; Stanojcic, S.; Lemaitre, J. M.; Mechali, M. A topoisomerase II-dependent mechanism for resetting replicons at the S-M-phase transition. Genes Dev. 2008, 22, 860-865.
55. Wulf, G. M.; Liou, Y. C.; Ryo, A.; Lee, S. W.; Lu, K. P. Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage. J. Biol. Chem. 2002, 277, 47976-47979.
56. Zacchi, P.; Gostissa, M.; Uchida, T.; Salvagno, C.; Avolio, F.; Volinia, S.; Ronai, Z.; Blandino, G.; Schneider, C.; Del Sal, G. The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature 2002, 419, 853-857.
57. Dwarakanath, B. S.; Manogaran, P. S.; Das, S.; Das, B. S.; Jain, V. Heterogeneity in DNA content & proliferative status of human brain tumours. Indian J. Med. Res. 1994, 100, 127-134.
58. Arevalo-Rodriguez, M.; Cardenas, M. E.; Wu, X.; Hanes, S. D.; Heitman, J. Cyclophilin A and Ess1 interact with and regulate silencing by the Sin3-Rpd3 histone deacetylase. EMBO J. 2000, 19, 3739-3749.
59. Pathan, N.; Aime-Sempe, C.; Kitada, S.; Haldar, S.; Reed, J. C. Microtubule-targeting drugs induce Bcl-2 phosphorylation and association with Pin1. Neoplasia 2001, 3, 70-79.
60. Chao, S. H.; Greenleaf, A. L.; Price, D. H. Juglone, an inhibitor of the peptidyl-prolyl isomerase Pin1, also directly blocks transcription. Nucleic Acids Res. 2001, 29, 767-773.